Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 19 (12), 74

Review of Immune Therapies Targeting Ovarian Cancer

Affiliations
Review

Review of Immune Therapies Targeting Ovarian Cancer

Cong Ava Fan et al. Curr Treat Options Oncol.

Abstract

The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term "immunotherapy" envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1-2 years.

Keywords: Adoptive immunotherapy; Anti-angiogenic; Atezolizumab; Avelumab; BRCA 1/2 mutation; Bevacizumab; CAR-T cells; CTLA-4; Cancer vaccine; Folate receptor alpha; Folate-binding protein; HER2; Immune checkpoint inhibitors; Immunotherapy; Ipilimumab; MAGE; Mesothelin; Microsatellite instability; Mirvetuximab soravtansine; NK cells; NY-ESO; Nivolumab; Ovarian cancer; PARP inhibitors; PD-L1; PD-L2; PD1; Pembrolizumab; T cells; TILS; p53.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
    1. Ann Oncol. 2017 Nov 1;28(suppl_8):viii36-viii39 - PubMed
    1. Cytokine Growth Factor Rev. 2013 Apr;24(2):147-61 - PubMed
    1. Front Immunol. 2018 Jan 05;8:1825 - PubMed
    1. J Clin Oncol. 2017 Jul 1;35(19):2193-2202 - PubMed

MeSH terms

Feedback